Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (40)COVID-19 (36)

Type

TypeGuidance (4955)Indicators (319)News (351)NICE advice (498)Quality standards (257)Research recommendations (1786)

Status

StatusAwaiting development (341)Discontinued (445)In consultation (14)In development (446)Published (2570)Topic prioritisation (384)

Last updated

Last updatedLast 3 months (206)Last 6 months (380)Last year (705)Last 3 years (1437)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (27)Antimicrobial resistance guidance (2)Cancer service guidelines (10)Clinical guidelines (392)COVID-19 rapid guidelines (27)Diagnostics guidance (89)Health technology evaluations (63)HealthTech guidance (767)Highly specialised technologies guidance (48)Interventional procedures guidance (1006)Medical technologies guidance (149)Medicines practice guidelines (5)NICE guidelines (579)Public health guidelines (89)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2309)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)NICE reviews (2)

Showing 2266 to 2280 of 8907 results

Sort by

Rezafungin for preventing invasive fungal infections after an allogeneic blood and marrow transplant [TSID12165]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Apremilast for treating juvenile psoriatic arthritis in people 5 to 17 years [TSID12089]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Botulinum neurotoxin type E for treating moderate to severe glabellar lines [TSID12155]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Diltiazem (Anatop, SLV-324, VEN 307) for Anal fissure [TSID 12100]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment [TSID12171]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Doravirine-islatravir for previously untreated HIV-1 infection [TSID12172]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy [TSID12173]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Orforglipron for treating type 2 diabetes [TSID12130]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation

Previous page
1
…
150
151
Current page 152
153
154
…
594
Page 152 of 594
Next page

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
BNF for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2026. All rights reserved. Subject to Notice of rights.